Consistent with at least some non-autonomous effects, SHP099 decreased tumor vascularity, as monitored by CD31 immunostaining, and the proliferation marker Ki67 also exhibited the weakest intensity in the group of combined inhibitors (Figure 4D). Here, MKI67 is linked to neoplasm.